Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDiploma Regulatory News (DPLM)

Share Price Information for Diploma (DPLM)

Share Price is delayed by 15 minutes
Get Live Data
7,130.00    80.00 (1.13%)
Bid:
7,110.00
Ask:
7,120.00
Spread: 10.00 (0.141%)
Market Cap: £9.56b
DPLM Live PriceLast checked at - London Stock Exchange

Intraday Diploma Share Chart

Interim Management Statement

13 Jan 2010 07:00

RNS Number : 4316F
Diploma PLC
13 January 2010
 



DIPLOMA PLC

12 CHARTERHOUSE SQUARE, LONDON EC1M 6AX

TELEPHONE: +44 (0)20 7549 5700

FACSIMILE: +44 (0)20 7549 5715

FOR IMMEDIATE RELEASE

13 January 2010

DIPLOMA PLC

INTERIM MANAGEMENT STATEMENT

Diploma PLC, the international group of businesses supplying specialised technical products and services, is today issuing its first Interim Management Statement of its new financial year, ahead of the Company's AGM to be held today at Brewers Hall, Aldermanbury Square, London, EC2V 7HR at 12.00 midday. This Statement relates to the period from 1 October 2009 to date and includes the first quarter's trading.

Trading

The Group has made a solid start to the new financial year with further evidence that key markets have stabilised. Revenues in the first quarter were 7% ahead of the comparable period last year and operating margins continued to benefit from cost reductions implemented last year. On an underlying basis, adjusting for currency effects and the acquisition of RTD Seals in January 2009, revenues for the first quarter remained unchanged from last year. 

The Life Sciences sector reported revenues 16% ahead of the prior comparable period driven by further growth in the Canadian Healthcare businesses and currency benefits. Revenue from the European environmental business remained stable.

The Seals sector reported revenues 11% ahead of the prior comparable period, benefiting from a full quarter contribution from RTD Seals; after adjusting for the acquisition of RTD Seals and currency effects, revenues were 4% below the comparable prior period. In North America and the UK, underlying revenues have stabilised and are showing signs of recovery. However, Continental European revenues were well below strong prior year comparatives, reflecting the later arrival of the economic downturn in these markets last year.

The Controls sector reported revenues 3% below the comparable prior period, again largely reflecting strong prior year comparatives from the Continental European businesses. The UK businesses achieved revenues broadly in line with the comparable period last year, with strong sales to Military Aerospace and Defence offsetting weaker activity in the general Industrial markets. 

Disposal of Anachem Limited 

The Group completed the disposal of the Manual Liquid Handling business of Anachem on 7 January 2010, as previously announced in the Group's Preliminary Statement on 16 November 2009. Cash proceeds of £7.8m were received on completion, of which £0.8m will be held in escrow. Further sale proceeds of up to £0.8m may be receivable, depending on the revenues earned in the twelve months ending 31 December 2010.

Acquisition of Minority Interests

Pursuant to the Sale and Purchase Agreement for the acquisition of Somagen Diagnostics Inc, dated 15 July 2004, the Group has now completed the acquisition of the final 8.8% of the outstanding shares in Somagen Diagnostics Inc from the minority shareholders for consideration of £2.5m (C$4.3m), following the exercise of put/call 

options, agreed at the time of acquisition. The Group's shareholding in Somagen Diagnostics Inc has now increased from 91.2% to 100%. The Group has also paid dividends to minority shareholders of ca £1.0m, of which £0.4m was paid during December 2009.

Financial Position

The improvement in underlying trading, together with the continuing focus on carefully managing any expansion in working capital, has resulted in another quarter of strong cash flow. At 31 December 2009, the Group's cash balances had increased to ca. £25.0m; this is before accounting for the proceeds from the sale of the Anachem business and the purchase of the minority interests in Somagen.

The Group also maintains a committed multi-currency facility of £20m which expires in November 2010; this will be reviewed during the next six months.

There have been no other significant changes in the position of the Group in the period since the publication of the Annual Report for the year ended 30 September 2009.

The next update on trading is expected to be issued as part of the Half Year results for the six months ending 31 March 2010, which are expected to be released on 10 May 2010.

Notes:

This Interim Management Statement, which is based upon unaudited management accounts, has been prepared solely to provide additional information to the shareholders of Diploma PLC in order to meet the requirements of the UK Listing Authority's Disclosure and Transparency Rules. It should not be relied on by any other party, for other purposes.

A copy of this Statement, together with further information about Diploma PLC, may be viewed on its website at www.diplomaplc.com

For further enquiries please contact:
 
 
 
Bruce Thompson, Chief Executive Officer
020 7549 5700
Nigel Lingwood, Group Finance Director
020 7549 5705
Simon Bloomfield, Bankside Consultants
020 7367 8861

 

NOTE TO EDITORS:

Diploma PLC is an international group of businesses supplying specialised technical products and services to the Life Sciences, Seals and Controls industries.

Diploma achieves stable growth and attractive margins from its focus on supplying specialised technical products to markets which value high levels of customer service, technical support and value adding activities. A high proportion of revenues are generated from essential products and services funded by operating, rather than capital budgets.

The Group employs ca. 825 employees and its principal operating businesses are located in the UK, Germany, US and Canada.

Over the last five years, the Group has grown adjusted earnings per share at an average of ca. 16% p.a. through a combination of organic growth and acquisitions. The current market capitalisation is ca. £200m.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSEASFAFLAEEFF
Date   Source Headline
16th Jan 202010:40 amRNSResult of AGM
15th Jan 20207:00 amRNSTrading Statement
24th Dec 20197:00 amRNSDirector / PDMR Grant of LTIP Award
23rd Dec 20197:00 amRNSDirectorate Change
17th Dec 20195:09 pmRNSHolding(s) in Company
16th Dec 201912:00 pmRNSHolding(s) in Company
6th Dec 20193:27 pmRNSAnnual Financial Report & Notice of AGM
21st Nov 20194:00 pmRNSDirector/PDMR Shareholding
18th Nov 20197:00 amRNSFinal Results
8th Oct 20197:00 amRNSDirectorate Change
25th Sep 20197:00 amRNSAcquisition
10th Sep 20194:49 pmRNSHolding(s) in Company
28th Aug 20197:00 amRNSTrading Statement
8th Aug 20193:00 pmRNSHolding(s) in Company
17th Jul 20191:01 pmRNSHolding(s) in Company
11th Jul 20197:00 amRNSAcquisition
13th Jun 20192:00 pmRNSDirector Declaration
13th May 20197:00 amRNSHalf-year Report
1st Apr 20197:00 amRNSAppointment of Joint Corporate Broker
27th Mar 20197:00 amRNSHalf Year Trading Update
26th Feb 20197:00 amRNSDirector/PDMR Shareholding
25th Feb 20194:00 pmRNSDirector/PDMR Shareholding
25th Feb 20197:00 amRNSDirectorate Appointments
29th Jan 20193:30 pmRNSDirector/PDMR Shareholding
16th Jan 20194:19 pmRNSResult of AGM
16th Jan 20197:01 amRNSDirectorate Change
16th Jan 20197:00 amRNSTrading Statement
7th Dec 20184:09 pmRNSDirector/PDMR Shareholding
7th Dec 20183:00 pmRNSAnnual Financial Report & Notice of AGM
27th Nov 20184:26 pmRNSDirector/PDMR Shareholding
19th Nov 20187:00 amRNSFinal Results
12th Oct 20187:00 amRNSAcquisition
3rd Sep 20184:45 pmRNSBoard Committee Change
29th Aug 20187:01 amRNSDirectorate Change
29th Aug 20187:00 amRNSTrading Statement
22nd Aug 20187:00 amRNSAcquisition
10th Jul 20181:46 pmRNSHolding(s) in Company
12th Jun 20182:59 pmRNSHolding(s) in Company
16th May 20182:41 pmRNSDirector Declaration
15th May 20184:20 pmRNSDirector/PDMR Shareholding
15th May 20184:09 pmRNSDirector/PDMR Shareholding
14th May 20187:00 amRNSHalf-year Report
9th May 20187:00 amRNSDirectorate Change
23rd Apr 20187:00 amRNSDirectorate Change
28th Mar 20187:00 amRNSTrading Update
21st Mar 20189:30 amRNSHolding(s) in Company
20th Mar 20184:00 pmRNSHolding(s) in Company
6th Feb 20189:49 amRNSDirector/PDMR Shareholding
30th Jan 20187:00 amRNSDirectorate Change
23rd Jan 20184:00 pmRNSDirector Declaration

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.